Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar Jaddyl (22.72) Submitted: 11/28/2012 11:29:59 AM : Outperform Start Price: $5.22 EXEL Score: -110.55

i'm expecting good long term growth with this stock.

Featured Broker Partners


Advertisement